The Food and Drug Administration (FDA) warns that the type 2 diabetes medicine canagliflozin (Invokana®, Invokamet®, Invokamet® XR) causes an increased risk of leg and foot amputations, based on data from two large clinical trials. As a result, the FDA now requires the makers of the drug to add a “black box” warning to the drug labels to better describe the risk of amputations to patients.
Prescribed for lowering an individual’s blood sugar, Invokana works by prompting the kidneys to remove sugar from the body through urine, and Invokana is one of the most common sodium-glucose co-transporter-2 (SGLT2) inhibitor brands.
Diabetics and Amputations
People with diabetes are typically at a greater risk of needing an amputation procedure, but clinical trials now reveal that the well-known medication Invokana may double the risk. While the reason behind why Invokana increases the chances of amputation is not clearly understood, researchers agree that Invokana, along with other risk factors makes needing an amputation more likely.
Did You Need an Amputation After Taking Invokana?
If you or a loved one took Invokana and later needed an amputation surgery, you could be entitled to compensation. Contact Sokolove Law today for a free, confidential legal consultation.
Invokana®, Invokamet®, Invokamet® XR are registered trademarks of Janssen Pharmaceuticals, Inc. Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.
